PCSK9 and cancer: In clinical trials on cardiovascular conditions, anti-PCSK9 antibodies evolocumab and alirocumab, which only block the activity of circulating PCSK9 primarily secreted from liver, did not reduce cancer incidence [45, 46], suggesting a much more complex narrative for PCSK9’s oncogenic actions that remains to be uncovered.